Protection of IFN-gamma signaling-deficient NOD mice from diabetes by cyclophosphamide

Int Immunol. 2008 Sep;20(9):1231-7. doi: 10.1093/intimm/dxn080. Epub 2008 Jul 21.

Abstract

Non-obese diabetic (NOD) mice that are genetically deficient in either IFN-gamma or beta chain of the IFN-gammaR develop diabetes with similar kinetics to wild-type NOD mice. In the current study, we demonstrated that treatment of IFN-gamma signaling-deficient NOD mice with cyclophosphamide (CY) not only fails to induce acute diabetes but also confers permanent protection from diabetes. Protection was mediated by the preferential generation of regulatory T cells (Treg cells) that are capable of suppressing the diabetogenic process, with no change in the total number and function of Treg cells. Moreover, CY treatment of IFN-gamma signaling-deficient NOD mice reversed the ongoing pathogenic process and eliminated cellular infiltrates of pancreatic islets. While these results have been derived using a genetically modified mouse model of diabetes, they indicate that knowledge of host genetic factors and environmental factors influencing the development of Type I diabetes mellitus may provide a rational approach to develop a means to reverse the development of Type I diabetes in human.

MeSH terms

  • Animals
  • Cyclophosphamide / administration & dosage*
  • Diabetes Mellitus, Experimental / etiology
  • Diabetes Mellitus, Experimental / genetics
  • Diabetes Mellitus, Experimental / prevention & control*
  • Diabetes Mellitus, Type 1 / etiology
  • Diabetes Mellitus, Type 1 / genetics
  • Diabetes Mellitus, Type 1 / prevention & control*
  • Immunosuppressive Agents / administration & dosage*
  • Interferon-gamma / deficiency*
  • Interferon-gamma / genetics
  • Islets of Langerhans / immunology
  • Mice
  • Mice, Inbred NOD
  • Mice, Knockout
  • T-Lymphocytes, Regulatory

Substances

  • Immunosuppressive Agents
  • Interferon-gamma
  • Cyclophosphamide